Core Insights - Liberty Defense Holdings Ltd. has announced a new contract for the deployment of its HEXWAVE™ system in Bogotá, Colombia, marking an expansion of its international presence [1][3] - The HEXWAVE system will enhance security at a major arena in Bogotá, which has seen an increase in violent incidents involving non-metallic threats [2][4] - The partnership with DASI Electronics S.A.S. aims to leverage advanced AI-powered detection technology to improve safety while maintaining a seamless visitor experience [2][3] Company Overview - Liberty Defense specializes in AI-based detection solutions for concealed weapons and threats, providing multi-technology security solutions for high-traffic areas [5] - The HEXWAVE product is based on exclusive technology licensed from the Massachusetts Institute of Technology (MIT) and offers modular, scalable protection against both metallic and non-metallic weapons [5] - The company is committed to enhancing community safety through superior security detection solutions and is exploring further opportunities for HEXWAVE deployment in high-security environments [3][4]

Company Overview - One and one Green Technologies, Inc. is a waste materials and scrap metal recycling company based in the Philippines, operating through Yoda Metal and Craft Trading and Services Corp. and DL Metal Corporation [4] - The company has a government-issued license to import hazardous waste as raw materials and an annual processing capacity of approximately 300,000 tons [5] Recent Developments - The company will ring the Nasdaq closing bell on October 24, 2025, to celebrate its recent initial public offering [1][2] - The event will be attended by corporate officers, executives, and board members, and will be broadcast live [2] Leadership Commentary - The Chairwoman and CEO, Ms. Caifen Yan, emphasized the significance of the Nasdaq bell ceremony as a milestone for the company's commitment to sustainable innovation in waste recycling [3] Environmental Technologies - One and one has developed environmentally friendly technologies, including an exhaust gas recirculation system approved by the Environmental Management Bureau of the Philippines, which enhances efficiency and reduces contamination [6] - The company aims to expand its sourcing of raw materials from Japan and South Korea and increase its presence in Southeast Asia and other international markets [6]

Core Insights - Crinetics Pharmaceuticals is presenting new data on paltusotine, a novel SST2 agonist, at the NANETS 2025 meeting, highlighting its potential anti-tumor effects in treating carcinoid syndrome associated with neuroendocrine tumors (NETs) [1][2] - The Phase 2 study of paltusotine shows a promising one-year progression-free survival rate of 74% in patients with carcinoid syndrome [2][4] - Paltusotine is currently approved in the U.S. for treating acromegaly but is not yet approved for carcinoid syndrome [3][5] Company Overview - Crinetics Pharmaceuticals focuses on developing therapies for endocrine diseases and related tumors, with a strong emphasis on targeting G-protein coupled receptors (GPCRs) [8][9] - The company has a diverse pipeline with over 10 disclosed programs, including late-stage candidates for various endocrine conditions [9] Clinical Development - Paltusotine is in Phase 3 clinical development for carcinoid syndrome, with previous studies indicating significant reductions in common symptoms such as flushing and bowel movement frequency [5][6] - The upcoming presentations at NANETS will include details from the Phase 3 trial of paltusotine and a first-in-human study of the nonpeptide drug candidate CRN09682 [4][6]

Core Insights - Beyond Air, Inc. will report its financial results for the second fiscal quarter ended September 30, 2025, on November 10, 2025, with a conference call scheduled for 4:30 PM ET on the same day [1] Company Overview - Beyond Air is a commercial-stage medical device and biopharmaceutical company focused on utilizing nitric oxide (NO) to enhance the lives of patients with respiratory illnesses, neurological disorders, and solid tumors [3] - The company has received FDA approval and CE Mark for its first system, LungFit PH, aimed at treating term and near-term neonates with hypoxic respiratory failure [3] - Beyond Air is advancing other LungFit systems in clinical trials for severe lung infections, including viral community-acquired pneumonia and nontuberculous mycobacteria [3] Partnerships and Research Initiatives - The company has partnered with The Hebrew University of Jerusalem to develop a pre-clinical program for treating autism spectrum disorder and other neurological disorders [4] - Beyond Cancer, Ltd., an affiliate of Beyond Air, is exploring ultra-high concentrations of NO with a proprietary delivery system targeting specific solid tumors in pre-clinical studies [4]

A presentation will be held via Teams 24/10 at 08.15 am CET, where the CEO presents the report. You can participate by register on the link below: Registration Form For further information about Nilörn, please contact: Krister Magnusson, CEO Tel: +46704-852 114. E-mail: krister.magnusson@nilorn.com General about Nilörn Group Nilörn Group is a global company, founded in the 1970s, with expertise in how to add value to brands through branding and design in the form of labels, packaging and accessories, primar ...

0749116 B.C. LTD.(DBA TERRA ROSSA GOLD LTD.) VANCOUVER, British Columbia, Oct. 23, 2025 (GLOBE NEWSWIRE) -- 0749116 B.C. Ltd. (formerly, Baroyeca Gold & Silver Inc.) (dba Terra Rossa Gold Ltd.) (the “Company”) (TSXV: TRR) is pleased to announce that as a result of the recent listing on the TSX.V under the symbol TRR, (see PR dated October 20, 2025), the Company is now well positioned to re-commence exploration and development work on its advanced stage Vetas Gold Project ("Vetas") located in Santander, Colo ...

Core Insights - Adtran has announced support for Galileo's Open Service Navigation Message Authentication (OSNMA), marking a significant advancement in GNSS security [1] - OSNMA is the first GNSS authentication service designed specifically for civilian use, highlighting its importance in enhancing security measures [1] - Adtran is the first company in the timing industry to support OSNMA, positioning itself as a leader in GNSS synchronization technology [1] Company Summary - Adtran's integration of OSNMA into its Oscilloquartz synchronization platforms demonstrates its commitment to improving the authenticity and integrity of timing data [1] - The support for OSNMA allows Adtran to verify that timing data originates from genuine Galileo satellites, which is crucial for maintaining trust in GNSS services [1]

Core Insights - Phathom Pharmaceuticals is participating in the ACG 2025 Annual Scientific Meeting to showcase its leadership in gastrointestinal treatments, particularly focusing on VOQUEZNA (vonoprazan) for GERD [1][2][3] Company Activities - The company will engage with the medical community through a product theater presentation on VOQUEZNA and will have a significant presence at the exhibit floor [2][3] - Phathom has organized an independent medical education program titled "Decision Points in the Management of GERD," scheduled for October 25, 2025 [5] Product Information - VOQUEZNA is a potassium-competitive acid blocker (PCAB) approved for treating various forms of GERD, including Erosive GERD and Non-Erosive GERD [6][25] - The product is marketed in the U.S. for multiple indications, including the relief of heartburn associated with Non-Erosive GERD and the healing of Erosive GERD [25] Safety and Efficacy - VOQUEZNA has been associated with several adverse reactions, including gastritis (3% in healing of Erosive GERD) and diarrhea (2% in relief of heartburn associated with Non-Erosive GERD) [20][21] - Important safety information includes contraindications for patients with hypersensitivity to vonoprazan and potential risks such as acute tubulointerstitial nephritis and Clostridioides difficile-associated diarrhea [6][10][11] Market Position - The company aims to build on the momentum for VOQUEZNA in the GERD treatment market by connecting with healthcare professionals and sharing clinical insights at the ACG meeting [3][25]

Core Insights - Teads has launched a beta version of CTV Performance, a solution that measures connected TV (CTV) campaign effectiveness by linking exposure to site visits, leads, and sales, marking a significant advancement in accountability for CTV advertising outside the US [1][2][3] Group 1: Product Features - CTV Performance allows advertisers to track metrics beyond traditional measures like impressions and completion rates, providing insights into direct actions such as site visits and sales linked to CTV exposure [2][3] - The solution is designed to complement Teads' existing omnichannel offerings, enabling brands to utilize premium streaming environments for both awareness and measurable mid-funnel outcomes [2][3] Group 2: Market Impact - The launch aims to bridge the gap between brand awareness and performance, democratizing CTV as a channel that can deliver both attention and measurable outcomes [3] - A recent campaign for Men's Wearhouse demonstrated the effectiveness of CTV Performance, resulting in over 41,000 site visits and more than 50,000 incremental store visits, showcasing CTV's potential in driving measurable results [3] Group 3: Availability and Expansion - CTV Performance is currently in beta across key global markets, including the US, EU5, and APAC, with plans for broader rollout and additional creative formats in the future [4]

Strategic expansion enhances service capabilities for retail, healthcare, and education customers while driving operational efficiency.KING OF PRUSSIA, Pa., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Clean Earth, a division of Enviri Corporation (NYSE: NVRI) and a leading provider of environmental and regulated waste management services, today announced the opening of a new service center in Syracuse, New York. The 18,400-square-foot warehouse, featuring 42 dock spaces, strengthens Clean Earth’s ability to serve a g ...